Upadacitinib shows greater improvement in PsA compared with adalimumab, placebo

Retrieved on: 2022-11-28 17:33:03

Tags for this article:

Click the tags to see associated articles and topics

Upadacitinib shows greater improvement in PsA compared with adalimumab, placebo. View article details on hiswai:

Excerpt

Disclosures: Coates reports receiving grants/research support from AbbVie, Amgen, Celgene, Janssen, Lilly, Novartis, Pfizer, and UCB; ...

Article found on: www.healio.com